Tandem Diabetes (TNDM) Misses Q2 EPS by 5c; Guides FY Revenue Below Views

Tandem Diabetes (NASDAQ: TNDM) reported Q2 EPS of ($0.55), $0.05 worse than the analyst estimate of ($0.50). Revenue for the quarter came in at $198.2 million versus the consensus estimate of $197.62 million.

GUIDANCE:

Tandem Diabetes sees FY2023 revenue of $785 million, versus the consensus of $881.47 million.

For earnings history and earnings-related data on Tandem Diabetes (TNDM) click here.

You May Also Be Interested In

• Nvidia pitches Vera CPU to Chinese clients with August delivery target
• Schwab's May activity shows margin loans nearly double
• UBS Reiterates Neutral Rating on Lennar (LEN) Following Q2 Results